MDSP Advocacy
Advocacy & Policy Watch
Legislation and policy affecting pathology in Maryland, DC, and nationwide.
Most recent source check:
A curated research snapshot. Items are reviewed manually; this page does not provide live or automatic updates.
5 items listed
No items currently listed.
Regulatory updates
Maryland · Regulatory guidance
Biomarker testing coverage
Maryland Insurance Administration guidance explains coverage requirements and evidence standards under Maryland’s existing biomarker testing law.
Why it matters to pathologyMolecular testing coverage and patient access, including avoiding disruption from repeated biopsies or specimen collection.
Issued
Regulatory guidance under existing law, not a pending bill.
Read guidance : Bulletin 26-15Last checked
Legislation to watch
| Bill / jurisdiction | Why it matters | Status / latest action | Sources |
|---|---|---|---|
| HB1126 · Maryland Health Insurance and Managed Care Organizations - Laboratory Services - Contract ProvidersWould address patients’ ability to choose laboratories, laboratory participation in insurance networks, and additional fees or conditions on laboratory services. | Why it matters to pathology Laboratory contracting, network participation, and patient choice. | Status / latest actionPast-session proposal No enactment shown in the official record. A proposed effective date does not establish enactment. Latest listed action · House hearing listing for March 19 at 2:30 p.m.; the listing does not confirm that a hearing occurred. | Sources Last checked |
| SB0608 · Maryland Maryland Medical Assistance Plan and Health Insurance - Pharmacogenomic Testing - Required CoverageWould require coverage for single-gene and multigene pharmacogenomic testing in specified circumstances. | Why it matters to pathology Access to molecular diagnostic testing. | Status / latest actionPast-session proposal Passed the Senate on March 20, 2026. No enactment shown in the official record. Latest listed action · House hearing for April 2 at 1 p.m. listed on March 25; the listing does not confirm that a hearing occurred. | Sources Last checked |
| H.R.8890 · Federal Enhancing Clinical Laboratory Innovation and Access Act of 2026Would establish a framework for laboratory-developed test oversight under CLIA, including federal oversight and test performance information. | Why it matters to pathology Laboratory-developed test (LDT) oversight, validation, and laboratory obligations. | Status / latest actionIntroduced Congress.gov lists this bill as introduced. The introduced House text is confirmed; introduction does not establish enactment. Latest listed action · Referred to the House Committees on Energy and Commerce and Ways and Means. | Sources Last checked |
| S.2761 · Federal RESULTS Act of 2025Would change how Medicare payment rates for clinical laboratory tests are determined, including private-payer data collection and rate calculations. | Why it matters to pathology Clinical Laboratory Fee Schedule reimbursement. | Status / latest actionIntroduced Congress.gov lists this bill as introduced. The introduced Senate text is confirmed; introduction does not establish enactment. Latest listed action · Read twice and referred to the Senate Committee on Finance. | Sources Last checked |
Tracking an item does not imply a society position.